Skip to content

Odyssey Evaluation in Post LASIK Patients

Study Evaluating Visual Outcomes in Post-Myopic LASIK Patients After Implantation of the Odyssey Intraocular Lens

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07260695
Enrollment
30
Registered
2025-12-03
Start date
2025-08-18
Completion date
2026-08-18
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

This prospective study evaluates the visual and refractive outcomes of the TECNIS Odyssey intraocular lens (IOL) implanted in patients with a history of myopic LASIK. Given the unique optical challenges of post-LASIK eyes, including altered corneal curvature and higher-order aberrations, the study aims to assess the IOL's performance in terms of distance, intermediate, and near vision, and patient satisfaction. Its design features may offer favorable outcomes in these patients.

Interventions

DEVICEOdyssey intraocular lens

The Odyssey intraocular lens is intended to be implanted at the time of cataract surgery to replace the natural lens.

Sponsors

Sengi Clinical
CollaboratorUNKNOWN
Center For Sight
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Subjects MUST fulfill the following conditions to qualify for enrollment into the trial 1. Age: 50 years and older. 2. Gender: Males and Females. 3. Bilateral cataracts 4. Bilateral implantation of Odyssey IOLs (toric and non-toric) 5. Scheduled to undergo standard cataract surgery in both eyes, within 1 to 30 days between surgeries. 6. Willing and able to provide written informed consent for participation in the study. 7. Willing and able to comply with scheduled visits and study examination procedures. 8. Postoperative best corrected visual acuity of 0.2 logMAR (20/32 Snellen) or better in each eye.

Exclusion criteria

Subjects with ANY of the following conditions on the eligibility exam may NOT be enrolled into the trial. 1. Established ocular pathology, including: glaucoma (except glaucoma suspects), uveitis, and clinically-significant retinal pathology affecting the macula (with visual acuity worse than 20/25) and/or any other ocular findings that may, in the opinion of the investigator, affect vision. 2. Uncontrolled diabetes. 3. Use of any systemic or topical drug known to interfere with visual performance. 4. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis. 5. Clinically significant corneal dystrophy. 6. Contact lens use during the active treatment portion of the trial. 7. Irregular astigmatism. 8. Corneal irregularities potentially affecting visual acuity (i.e., keratoconus, corneal opacities 9. History of chronic intraocular inflammation. 10. History of retinal detachment. 11. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules. 12. Previous intraocular surgery. 13. Previous keratoplasty 14. Previous refractive surgery other than myopic LASIK or PRK (i.e., radial keratotomy, hyperopic LASIK, etc) 15. Severe dry eye. 16. Pupil abnormalities. 17. Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e., LASIK). 18. Any clinically significant, serious, or severe medical or psychiatric condition that may interfere with the interpretation of study results. 19. Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial. 20. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.) 21. Abnormal iris The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates the patient is unsuitable for the trial.

Design outcomes

Primary

MeasureTime frameDescription
Binocular defocus curve3 months postoperativelyThe defocus curve assesses a patient's visual performance at various distances by introducing different levels of lens defocus (measured in diopters) and recording the corresponding visual acuity. It provides a comprehensive evaluation of the range of clear vision (distance, intermediate, and near) offered by an intraocular lens.

Secondary

MeasureTime frameDescription
Patient satisfaction3 months postoperativelyPercentage of patients who reported being completely, mostly, moderately, a little or not at all satisfied with overall vision
Spectacle independence at near.3 months postoperativelyPercentage of patients who reported wearing glasses none of the time or a little of the time for near activities (16 inches/40 cm).

Countries

United States

Contacts

Primary ContactHelga P Sandoval
hps@cepmd.com8438813937

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026